CSIMarket Company Name, Ticker, Competitors, else..
 
Applied Therapeutics Inc   (APLT)
Other Ticker:  
 
 
Price: $10.2100 $0.62 6.465%
Day's High: $10.48 Week Perf: 8.27 %
Day's Low: $ 9.45 30 Day Perf: 18.31 %
Volume (M): 2,472 52 Wk High: $ 10.62
Volume (M$): $ 25,237 52 Wk Avg: $5.52
Open: $9.58 52 Wk Low: $1.85



 Market Capitalization (Millions $) 1,474
 Shares Outstanding (Millions) 144
 Employees 71
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -187
 Cash Flow (TTM) (Millions $) 61
 Capital Exp. (TTM) (Millions $) 0

Applied Therapeutics Inc
Applied Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics for the treatment of serious diseases. The company aims to address unmet medical needs by targeting specific pathways to restore health and improve patient outcomes. Applied Therapeutics Inc utilizes a multi-disciplinary approach, combining expertise in drug development, clinical pharmacology, and translational medicine to advance its pipeline of therapeutic candidates. The company's research and development efforts primarily focus on therapies for glycobiology-related diseases, such as diabetic complications and rare genetic disorders.


   Company Address: 545 Fifth Avenue New York 10017 NY
   Company Phone Number: 220-9226   Stock Exchange / Ticker: NASDAQ APLT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        1.11% 
JNJ   -0.79%    
LLY        5.38% 
MRK   -0.35%    
TEVA   -2.58%    
VTRS   -0.38%    
• View Complete Report
   



Clinical Study

FDAs Complete Response Letter Challenges Applied Therapeutics Path Forward for Govorestat in Classic Galactosemia T...

Published Wed, Nov 27 2024 9:10 PM UTC

FDA Issues Complete Response Letter to Applied Therapeutics Govorestat NDA for Classic Galactosemia TreatmentIn a move that underscores the rigorous scrutiny involved in approving novel therapeutics, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Applied Therapeutics, Inc. regarding their New Drug Application (NDA) for govorestat...
Clinical Study

Applied Therapeutics Pioneering Breakthroughs in Rare Disease Treatment with Govorestat,

Published Wed, Sep 18 2024 11:01 AM UTC

Navigating New Frontiers in Rare Disease Treatment: Applied Therapeutics Promising Developments Applied Therapeutics Provides Regulatory Updates and Positive Interim Results for Govorestat Late-Cycle Review Meeting with FDA Completed for Govorestat in Treating Classic Galactosemia Applied Therapeutics recently reached an important milestone in its journey to bring Govores...
Applied Therapeutics Inc

Major Pharmaceutical Preparations Company Faces Steep Decline in Revenue During First Quarter of 2024

Applied Therapeutics Inc, a major pharmaceutical preparations company, recently reported a disastrous fiscal period. The company's revenue plummeted by a staggering 98.218% to $0.19 million, and their net deficit per share widened to $-0.67, compared to the previous reporting season's $-0.34 per share. However, there was a glimmer of hope as revenue turned positive, albeit at $-0.67 million.
Despite these disappointing financial results, Applied Therapeutics Inc has been making significant strides in its drug development pipeline. The company recently announced that it will present full results from the Phase 3 ARISE-HF study at the 2024 American College of Cardiology (ACC) Annual Scientific Session. The study evaluated AT-001 (caficrestat) in treating Diabetic Cardiomyopathy, a condition with high unmet medical need. This presentation indicates the company's commitment to addressing significant medical challenges and finding potential solutions.
Product Service News

Applied Therapeutics' Govorestat for Classic Galactosemia Sees Extended FDA Review Period, Showcases Growth Potential in Revenue

Published Thu, Mar 28 2024 8:30 PM UTC

In recent news, Applied Therapeutics, a clinical-stage biopharmaceutical company, announced an update regarding the New Drug Application (NDA) for govorestat (AT-007), a potential treatment for Classic Galactosemia. The U.S. Food and Drug Administration (FDA) has extended the review period for the NDA by three months, setting a new target action date of November 28, 2024. Th...
Applied Therapeutics Inc

APLT Achieves Milestone with FDA Acceptance of NDA for Govorestat

Applied Therapeutics Inc. (Nasdaq: APLT) has recently made significant advancements in its drug development pipeline, particularly with the FDA's acceptance and priority review of their New Drug Application (NDA) for Govorestat, an investigational drug for the treatment of Classic Galactosemia. This rare metabolic disorder affects individuals who are unable to properly metabolize galactose, leading to serious health complications. The potential approval of Govorestat offers hope for patients suffering from this debilitating condition.
The acceptance of the NDA represents a crucial step towards potential regulatory approval for Govorestat. Applied Therapeutics Inc. is dedicated to developing innovative drug candidates targeting validated molecular targets in areas with high unmet medical needs. The Company's commitment to addressing rare diseases like Classic Galactosemia highlights their dedication to improving the lives of patients with limited treatment options.






Applied Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com